174 related articles for article (PubMed ID: 11920753)
1. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.
Shibata N; Gao W; Okamoto H; Kishida T; Iwasaki K; Yoshikawa Y; Takada K
J Pharm Sci; 2002 Mar; 91(3):680-9. PubMed ID: 11920753
[TBL] [Abstract][Full Text] [Related]
2. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
5. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
[TBL] [Abstract][Full Text] [Related]
7. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Gao W; Kageyama M; Inoue Y; Tadano J; Fukumoto K; Fukushima K; Yamasaki D; Nishimura A; Yoshikawa Y; Shibata N; Takada K
Biol Pharm Bull; 2003 Feb; 26(2):199-204. PubMed ID: 12576680
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Droste JA; Verweij-Van Wissen CP; Burger DM
Ther Drug Monit; 2003 Jun; 25(3):393-9. PubMed ID: 12766571
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of the five HIV-protease inhibitors: amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography.
Poirier JM; Radembino N; Robidou P; Jaillon P
Ther Drug Monit; 2000 Aug; 22(4):465-73. PubMed ID: 10942189
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.
Lledó-García R; Nácher A; Casabó VG; Merino-Sanjuán M
Drug Metab Dispos; 2011 Feb; 39(2):294-301. PubMed ID: 20978105
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.
Dailly E; Thomas L; Kergueris MF; Jolliet P; Bourin M
J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(2):129-35. PubMed ID: 11486821
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
Yamada H; Kotaki H; Nakamura T; Iwamoto A
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):85-9. PubMed ID: 11393736
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
Kempf DJ; Marsh KC; Kumar G; Rodrigues AD; Denissen JF; McDonald E; Kukulka MJ; Hsu A; Granneman GR; Baroldi PA; Sun E; Pizzuti D; Plattner JJ; Norbeck DW; Leonard JM
Antimicrob Agents Chemother; 1997 Mar; 41(3):654-60. PubMed ID: 9056009
[TBL] [Abstract][Full Text] [Related]
17. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Kuschak D; Mauss S; Schmutz G; Gantke B
Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
[TBL] [Abstract][Full Text] [Related]
19. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
[TBL] [Abstract][Full Text] [Related]
20. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
